GRPHGraphite BioGRPH info
$30.28info3.56%24h
Global rank5639
Market cap$1.76B
Change 7d-2.20%
YTD Performance1069.11%
SP500 benchmarkOutperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Business data

    Graphite Bio (GRPH) Stock Overview

    Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH102 for the treatment of beta-thalassemia; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

    GRPH Stock Information

    Symbol
    GRPH
    Address
    201 Haskins WaySouth San Francisco, CA 94080United States
    Founded
    -
    Trading hours
    -
    Website
    https://graphitebio.com
    Country
    πŸ‡ΊπŸ‡Έ United States
    Phone Number
    650 484 0886

    Graphite Bio (GRPH) Price Chart

    -
    Value:-

    Graphite Bio Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $30.28
    N/A
    Market Cap
    $1.76B
    N/A
    Shares Outstanding
    58.00M
    N/A
    Employees
    120.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org